← Browse by Condition
Medical Condition

relapsed acute myelogenous leukemia

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1

Leukemia clinical trials cover acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) — distinct diseases with profoundly different biology and treatment approaches. AML research focuses on targeted agents for FLT3, IDH1/2, and TP53-mutated disease, while CLL trials explore fixed-duration venetoclax combinations that achieve treatment-free remissions.

Active trials investigate menin inhibitors for NPM1/KMT2A AML, magrolimab (anti-CD47) combinations, bispecific antibodies in relapsed ALL, and next-generation BTK inhibitors (pirtobrutinib) for ibrutinib-resistant CLL. MRD (minimal residual disease) negativity is emerging as a regulatory endpoint to accelerate approvals.

Trial Phases
Phase 1
1
Top Sponsors
Hangzhou Weben Pharma Co., Ltd 1 trial

Recruiting Clinical Trials

NCT07014449 Phase 1
Recruiting

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

Enrollment
18 pts
Location
China
Sponsor
Hangzhou Weben Pharma Co., Ltd
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology